Abstract
Clinical studies of MDMA have been hindered by the fear of harming participants through MDMA-induced neurotoxicity. However, experimental animal studies and brain imaging studies of recreational Ecstasy users have not evidenced that a therapeutic dose of MDMA would be sufficient to cause long-term serotonergic deficits. Furthermore, the issue of potential neurotoxicity may not be as important as it first seems since certain chemicals have been shown to protect against MDMA-induced neurotoxicity. Although clinical studies conducted thus far have been promising, more research into the effects of MDMA administration in humans is needed before solid conclusions can be made in respect to the possibility of safely using MDMA as an adjunct to therapy. Finally, a clear distinction should be maintained between the recreational and clinical use of MDMA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
